Next Article in Journal
Ftr82 Is Critical for Vascular Patterning during Zebrafish Development
Next Article in Special Issue
A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments
Previous Article in Journal
Bone Niches, Hematopoietic Stem Cells, and Vessel Formation
Previous Article in Special Issue
Correlations between Endomyocardial Biopsies and Cardiac Manifestations in Taiwanese Patients with the Chinese Hotspot IVS4+919G>A Mutation: Data from the Fabry Outcome Survey

Osteocyte Alterations Induce Osteoclastogenesis in an In Vitro Model of Gaucher Disease

Instituto de Estudios Inmunológicos y Fisiopatológicos (IIFP), CONICET-UNLP, 1900 La Plata, Argentina
Instituto de Inmunología, Genética y Metabolismo (INIGEM), Hospital de Clínicas “José de San Martín”, Facultad de Medicina, CONICET-Universidad de Buenos Aires, Paraguay 2155, C1121ABG Buenos Aires, Argentina
Author to whom correspondence should be addressed.
Both authors contributed equally to carrying out the experiments and to the interpretation and analysis of results.
Both authors contributed equally to the project and experiment design, result analysis and interpretation, and paper editing.
Academic Editor: Ritva Tikkanen
Int. J. Mol. Sci. 2017, 18(1), 112;
Received: 17 October 2016 / Revised: 30 December 2016 / Accepted: 2 January 2017 / Published: 13 January 2017
Gaucher disease (GD) is caused by mutations in the glucosylceramidase β (GBA 1) gene that confer a deficient level of activity of glucocerebrosidase (GCase). This deficiency leads to the accumulation of the glycolipid glucocerebroside in the lysosomes of cells, mainly in the monocyte/macrophage lineage. Its mildest form is Type I GD, characterized by non-neuronopathic involvement. Bone compromise is the most disabling aspect of the Gaucher disease. However, the pathophysiological aspects of skeletal alterations are not yet fully understood. The bone tissue homeostasis is maintained by a balance between resorption of old bone by osteoclasts and new bone formation by osteoblasts. A central player in this balance is the osteocyte as it controls both processes. We studied the involvement of osteocytes in an in vitro chemical model of Gaucher disease. The osteocyte cell line MLO-Y4 was exposed to conduritol-β-epoxide (CBE), an inhibitor of GCase, for a period of 7, 14 and 21 days. Conditioned media from CBE-treated osteocytes was found to induce osteoclast differentiation. GCase inhibition caused alterations in Cx43 expression and distribution pattern and an increase in osteocyte apoptosis. Osteoclast differentiation involved osteocyte apoptotic bodies, receptor activator of nuclear factor κ-B ligand (RANKL) and soluble factors. Thus, our results indicate that osteocytes may have a role to play in the bone pathophysiology of GD. View Full-Text
Keywords: Gaucher disease; bone; osteocyte; osteoclast; apoptotic bodies Gaucher disease; bone; osteocyte; osteoclast; apoptotic bodies
Show Figures

Graphical abstract

MDPI and ACS Style

Bondar, C.; Ormazabal, M.; Crivaro, A.; Ferreyra-Compagnucci, M.; Delpino, M.V.; Rozenfeld, P.A.; Mucci, J.M. Osteocyte Alterations Induce Osteoclastogenesis in an In Vitro Model of Gaucher Disease. Int. J. Mol. Sci. 2017, 18, 112.

AMA Style

Bondar C, Ormazabal M, Crivaro A, Ferreyra-Compagnucci M, Delpino MV, Rozenfeld PA, Mucci JM. Osteocyte Alterations Induce Osteoclastogenesis in an In Vitro Model of Gaucher Disease. International Journal of Molecular Sciences. 2017; 18(1):112.

Chicago/Turabian Style

Bondar, Constanza, Maximiliano Ormazabal, Andrea Crivaro, Malena Ferreyra-Compagnucci, María V. Delpino, Paula A. Rozenfeld, and Juan M. Mucci 2017. "Osteocyte Alterations Induce Osteoclastogenesis in an In Vitro Model of Gaucher Disease" International Journal of Molecular Sciences 18, no. 1: 112.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop